chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 20.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Fatigue, Headache, Nasal congestion, Oropharyngeal pain
Clinical narrative: Sore throat; Fatigue; Runny nose; Congestion; Headaches; Coughing; Pain in lungs when coughing; This is a spontaneous report from a contactable consumer, the patient. A 20-year-old, male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 26Apr2021 at 17:00 (at the age of 20-year-old) as a single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccination within 4 weeks prior to the COVID-19 vaccine. On 29Apr2021 at 12:00, the patient experienced sore throat, fatigue, followed by runny nose, congestion, headaches, coughing and pain in the lungs when coughing. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visits, and the emergency room/department or urgent care. Since the vaccination, the patient was not tested for COVID-19. The clinical outcome of the events sore throat, fatigue, runny nose, congestion, headaches, coughing and pain in lungs when coughing were resolving at the time of the report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 20.0
Sex: M
Vaccine: COVID19
Symptoms: Pulmonary pain, Rhinorrhoea
Clinical narrative: Sore throat; Fatigue; Runny nose; Congestion; Headaches; Coughing; Pain in lungs when coughing; This is a spontaneous report from a contactable consumer, the patient. A 20-year-old, male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 26Apr2021 at 17:00 (at the age of 20-year-old) as a single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccination within 4 weeks prior to the COVID-19 vaccine. On 29Apr2021 at 12:00, the patient experienced sore throat, fatigue, followed by runny nose, congestion, headaches, coughing and pain in the lungs when coughing. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visits, and the emergency room/department or urgent care. Since the vaccination, the patient was not tested for COVID-19. The clinical outcome of the events sore throat, fatigue, runny nose, congestion, headaches, coughing and pain in lungs when coughing were resolving at the time of the report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Dizziness, Heart rate, Heart rate increased, SARS-CoV-2 test
Clinical narrative: Elevated heart rate (resting ~105); Dizziness; Weakness; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 28Apr2021 at 08:30 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes mellitus (diabetes T2), asthma, hypertension and Gastroesophageal Reflux Disease (GERD). The patient had no known allergies. Concomitant medications included metformin (MANUFACTURER UNKNOWN), glimepiride (MANUFACTURER UNKNOWN) and empagliflozin (JARDIANCE), all taken for unspecified indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 07Apr2021 at 15:45 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021, the patient underwent rapid COVID-19 test (nasal swab) and the result was negative. On 01May2021 at 12:00, the patient experienced elevated heart rate (resting - 105), dizziness and weakness. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events elevated heart rate, dizziness and weakness were not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Fatigue, Headache, Nausea
Clinical narrative: This is a spontaneous report from a noncontactable consumer (patient). A 43-year-old (non-pregnant) female patient received the second dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine: batch/lot# unknown), at the age of 43, via an unspecified route of administration, left arm, on Apr 30, 2021, single dose, for COVID-19 immunisation. Medical history and concomitant medications not reported. Prior to the vaccination, patient was not diagnosed with COVID-19. The patient previously received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine, batch/lot# unknown), at the age of 43, via an unspecified route of administration, left arm, on Apr 9, 2021, single dose, for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On Apr 30, 2021, patient experienced fatigue, fever, chills, joint pain, skin aches, pains, headache and nausea. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient has not tested for COVID-19. The outcome of fatigue, fever, chills, joint pain, skin aches, pains, headache and nausea: recovering (at the time of this report). No follow-up attempts possible. Information about lot/batch number cannot be obtained. No further information expected
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pain of skin, Pyrexia
Clinical narrative: This is a spontaneous report from a noncontactable consumer (patient). A 43-year-old (non-pregnant) female patient received the second dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine: batch/lot# unknown), at the age of 43, via an unspecified route of administration, left arm, on Apr 30, 2021, single dose, for COVID-19 immunisation. Medical history and concomitant medications not reported. Prior to the vaccination, patient was not diagnosed with COVID-19. The patient previously received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine, batch/lot# unknown), at the age of 43, via an unspecified route of administration, left arm, on Apr 9, 2021, single dose, for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On Apr 30, 2021, patient experienced fatigue, fever, chills, joint pain, skin aches, pains, headache and nausea. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient has not tested for COVID-19. The outcome of fatigue, fever, chills, joint pain, skin aches, pains, headache and nausea: recovering (at the time of this report). No follow-up attempts possible. Information about lot/batch number cannot be obtained. No further information expected
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Dyskinesia, Eyelid disorder, Hypoaesthesia, Paraesthesia, Reduced facial expression
Clinical narrative: Numbness; tingling and drooping on the entire right side of my face will move.; My eyelid won't close; my mouth doesn't move and only the left side of my face will move.; my mouth doesn't move and only the left side of my face will move.; This is a spontaneous report received from a contactable consumer or other non hcp (patient). A 28-years-old male patient received 2nd dose of bnt162b2 (Pfizer biontech covid19 vaccine,Batch/Lot Number: EW0151),via an unspecified route of administration, administered in Arm Left on 15Apr2021 14:30(at the age of 28-year-old) as Dose 2,single for covid-19 immunization. Medical history was none. The patient concomitant medications were not reported. Patient previously received his 1st dose of Pfizer covid-19 vaccine in 25Mar2021 01:30 pm, Lot number: ER8730,on his left arm  On 29Apr2021 06:45 the patient experienced numbness, tingling and drooping on the entire right side of his face will move, his eyelid won't close and his mouth doesn't move and only the left side of his face will move. Therapeutic measures were taken as a result of events. The patient didn't receive any other vaccine within 4 weeks prior to covid 19 vaccination. The patient was not diagnosed with covid prior to vaccination. The patient was not tested for covid19 after vaccination. Adverse event didn't result in physician clinic and emergency room visit. The outcome of the events was not recovered.   No follow-up attempts are possible. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Pain in extremity, Peripheral swelling
Clinical narrative: right pointer finger swollen and sore; right pointer finger swollen and sore; "Dose 1, administration date: 06Apr2021; Dose 2, administration date: 21Apr2021"; This is a spontaneous report from a non-contactable consumer, the patient. A 28-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 21Apr2021 at 12:00 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient did not have allergies to medications, food, or other products. The patient did not receive any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 06Apr2021 at 14:30 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021 at 12:00, the patient had "Dose 1, administration date: 06Apr2021; Dose 2, administration date: 21Apr2021". On 22Apr2021 at 10:00, the patient experienced right pointer finger swollen and sore since the day after the second shot. The swelling had not subsided at all over the last 10 days. The patient experienced no other side effects.The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events right pointer finger swollen and sore were not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Hyperventilation, Nausea, Panic attack, Tremor
Clinical narrative: panic attack; Hyperventilation; Shaking; dizzy; Nauseous; This is a spontaneous report from a contactable pharmacist. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via intramuscular route in the left arm on 01May2021 at 09:30 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, high cholesterol and anxiety. It was unknown if the patient had allergies to medications, food, or other products. Concomitant medications included escitalopram (MANUFACTURER UNKNOWN), lisinopril (MANUFACTURER UNKNOWN) and atorvastatin (MANUFACTURER UNKNOWN); all taken from an unknown date for unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EW0151) intramuscularly in the left arm on 10Apr2021 at 09:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19.  It was unknown whether the patient had received any other vaccines within four weeks prior to the vaccination. On 01May2021 at 09:30, the patient had panic attack following vaccine - hyperventilation, shaking, dizzy and nauseous. Requested 911 to be called, first responders arrived and took her out on a stretcher. The patient remained conscious the whole time. The event resulted in emergency room/department or urgent care. Therapeutic measures were taken as a result of the events and was given water, stayed seated, and was told to take deep breaths/allowed to use inhaler. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The clinical outcome of the events panic attack, hyperventilation, shaking, dizzy and nauseous were unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood test, Dizziness, Headache, Magnetic resonance imaging, Urine analysis
Clinical narrative: Dizzy symptoms 9 days after vaccine; Headache; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 22Apr2021 at 13:15 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. The medical history included hashimoto's thyroiditis, allergy to penicillin, gluten and stinging insects. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other vaccine within four weeks prior to the vaccination. The concomitant medications included  thyroid (ARMOUR THYROID), naltrexone (LOW DOSE NALTREXONE) and vitamin d nos (VITAMIN D), all from unknown dates for unknown indications and tetanus vaccine toxoid, diphtheria vaccine toxoid, pertussis vaccine acellular (TDAP) in arm left on 06Apr2021 for an unknown indication. The patient previously took paracetamol, oxycodone hydrochloride(PERCOCET) on an unknown date and experienced allergy. On 01May2021 at 06:00, 9 days after the vaccination, the patient experienced dizzy symptoms and headache. On an unknown date, the patient underwent blood work, urine test and MRI (Magnetic resonance imaging) tests and the result was unknown. The adverse events resulted in emergency room/department or urgent care visit. Therapeutic measures were taken as a result of reported events were unknown. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event dizzy symptoms and headache was recovered with sequelae on 01May2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Angiogram, Angiogram cerebral, Autonomic nervous system imbalance, Balance disorder, Brain stem auditory evoked response
Clinical narrative: Dizzy symptoms 9 days after vaccine; Headache; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 22Apr2021 at 13:15 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. The medical history included hashimoto's thyroiditis, allergy to penicillin, gluten and stinging insects. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other vaccine within four weeks prior to the vaccination. The concomitant medications included  thyroid (ARMOUR THYROID), naltrexone (LOW DOSE NALTREXONE) and vitamin d nos (VITAMIN D), all from unknown dates for unknown indications and tetanus vaccine toxoid, diphtheria vaccine toxoid, pertussis vaccine acellular (TDAP) in arm left on 06Apr2021 for an unknown indication. The patient previously took paracetamol, oxycodone hydrochloride(PERCOCET) on an unknown date and experienced allergy. On 01May2021 at 06:00, 9 days after the vaccination, the patient experienced dizzy symptoms and headache. On an unknown date, the patient underwent blood work, urine test and MRI (Magnetic resonance imaging) tests and the result was unknown. The adverse events resulted in emergency room/department or urgent care visit. Therapeutic measures were taken as a result of reported events were unknown. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event dizzy symptoms and headache was recovered with sequelae on 01May2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Cytokine increased, Eustachian tube disorder, Head discomfort, Headache, Heart rate increased
Clinical narrative: Dizzy symptoms 9 days after vaccine; Headache; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 22Apr2021 at 13:15 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. The medical history included hashimoto's thyroiditis, allergy to penicillin, gluten and stinging insects. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other vaccine within four weeks prior to the vaccination. The concomitant medications included  thyroid (ARMOUR THYROID), naltrexone (LOW DOSE NALTREXONE) and vitamin d nos (VITAMIN D), all from unknown dates for unknown indications and tetanus vaccine toxoid, diphtheria vaccine toxoid, pertussis vaccine acellular (TDAP) in arm left on 06Apr2021 for an unknown indication. The patient previously took paracetamol, oxycodone hydrochloride(PERCOCET) on an unknown date and experienced allergy. On 01May2021 at 06:00, 9 days after the vaccination, the patient experienced dizzy symptoms and headache. On an unknown date, the patient underwent blood work, urine test and MRI (Magnetic resonance imaging) tests and the result was unknown. The adverse events resulted in emergency room/department or urgent care visit. Therapeutic measures were taken as a result of reported events were unknown. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event dizzy symptoms and headache was recovered with sequelae on 01May2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Magnetic resonance imaging head, Pain, Post-acute COVID-19 syndrome, Postural orthostatic tachycardia syndrome, SARS-CoV-2 test negative
Clinical narrative: Dizzy symptoms 9 days after vaccine; Headache; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 22Apr2021 at 13:15 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. The medical history included hashimoto's thyroiditis, allergy to penicillin, gluten and stinging insects. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other vaccine within four weeks prior to the vaccination. The concomitant medications included  thyroid (ARMOUR THYROID), naltrexone (LOW DOSE NALTREXONE) and vitamin d nos (VITAMIN D), all from unknown dates for unknown indications and tetanus vaccine toxoid, diphtheria vaccine toxoid, pertussis vaccine acellular (TDAP) in arm left on 06Apr2021 for an unknown indication. The patient previously took paracetamol, oxycodone hydrochloride(PERCOCET) on an unknown date and experienced allergy. On 01May2021 at 06:00, 9 days after the vaccination, the patient experienced dizzy symptoms and headache. On an unknown date, the patient underwent blood work, urine test and MRI (Magnetic resonance imaging) tests and the result was unknown. The adverse events resulted in emergency room/department or urgent care visit. Therapeutic measures were taken as a result of reported events were unknown. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event dizzy symptoms and headache was recovered with sequelae on 01May2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tremor, Ultrasound Doppler, Vertigo
Clinical narrative: Dizzy symptoms 9 days after vaccine; Headache; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 22Apr2021 at 13:15 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. The medical history included hashimoto's thyroiditis, allergy to penicillin, gluten and stinging insects. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other vaccine within four weeks prior to the vaccination. The concomitant medications included  thyroid (ARMOUR THYROID), naltrexone (LOW DOSE NALTREXONE) and vitamin d nos (VITAMIN D), all from unknown dates for unknown indications and tetanus vaccine toxoid, diphtheria vaccine toxoid, pertussis vaccine acellular (TDAP) in arm left on 06Apr2021 for an unknown indication. The patient previously took paracetamol, oxycodone hydrochloride(PERCOCET) on an unknown date and experienced allergy. On 01May2021 at 06:00, 9 days after the vaccination, the patient experienced dizzy symptoms and headache. On an unknown date, the patient underwent blood work, urine test and MRI (Magnetic resonance imaging) tests and the result was unknown. The adverse events resulted in emergency room/department or urgent care visit. Therapeutic measures were taken as a result of reported events were unknown. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event dizzy symptoms and headache was recovered with sequelae on 01May2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Chest pain, Nipple pain
Clinical narrative: a little pain on the lower nipple; I have like a pinch in my heart in a little pain on the lower nipple; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old male patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0161) via an unspecified route of administration on 17Apr2021 at 13:00 as a single dose for COVID-19 immunisation. The patient had not reported any other health issue. The patient did not have any known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021, the patient experienced pinch in heart in a little pain on the lower nipple. It was unknown whether any therapeutic measures were taken as a result of the event. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event pinch in heart in a little pain on the lower nipple was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Hypokinesia
Clinical narrative: About 5 hours after receiving the vaccine, I started having pain in my left shoulder (I couldn't lift my arm at all) and excruciating pain in my right knee and hip.; About 5 hours after receiving the vaccine, I started having pain in my left shoulder (I couldn't lift my arm at all) and excruciating pain in my right knee and hip. It was so bad, I couldn't step on my right leg.; About 5 hours after receiving the vaccine, I started having pain in my left shoulder (I couldn't lift my arm at all) and excruciating pain in my right knee and hip. It was so bad, I couldn't step on my right leg.; About 5 hours after receiving the vaccine, I started having pain in my left shoulder (I couldn't lift my arm at all) and excruciating pain in my right knee and hip. It was so bad, I couldn't step on my right leg.; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 26Apr2021 at 08:45 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient no known allergies to medications, food, or other products. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Apr2021 at 14:00, about five hours after receiving the vaccine, the patient started having pain in her left shoulder (she couldn't lift her arm at all) and excruciating pain in her right knee and hip. It was so bad, the patient couldn't step on her right leg. The pain started decreasing after about 24 hours, went away all together after three days on 29Apr2021. No therapeutic measures were taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events about five hours after receiving the vaccine, the patient started having pain in her left shoulder (she couldn't lift her arm at all) and excruciating pain in her right knee and hip; it was so bad, the patient couldn't step on her right leg; the pain started decreasing after about 24 hours, went away all together was resolved after three days on 29Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Blood test, Lymphadenopathy, Ultrasound scan
Clinical narrative: Lymphadenopathy persisting at least 11+ weeks  post vaccination-supraclavicular LN >4 cm on long axis; This is a spontaneous report from a contactable other healthcare professional, the patient. A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EK9231) via an unspecified route of administration in the left arm on 13Jan2021 at 10:00 (at the age of 39-year-old) and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9264) via an unspecified route of administration in the left arm on an unknown date in 2021  (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history included allergy to sunscreen. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included naltrexone hydrochloride, bupropion hydrochloride (CONTRAVE) from unknown date for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Mar2021 the patient experienced Lymphadenopathy persisting at least 11 plus weeks post vaccination-supraclavicular Lymph Node greater than 4 cm on long axis and bloodwork normal. The event resulted in doctor or other healthcare professional office/clinic visit. It was unknown if patient received treatment for the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event Lymphadenopathy was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Dysgeusia, Parosmia
Clinical narrative: Metallic taste in mouth; Metallic taste in mouth and smell in nose; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW01710) via an unspecified route of administration in the left arm on 22Apr2021 at 10:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. The patient has not reported any other health issues. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 31Mar2021 at 10:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 23Apr2021 at 08:00, the patient experienced metallic taste in mouth and smell in nose. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the event metallic taste in mouth and smell in nose was recovered on an unknown date in 2021 at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Decreased appetite, Fatigue, Myalgia, Nausea
Clinical narrative: Muscle and body aches; Nausea; Decreased appetite; Gastrointestinal upset; Fatigue; body aches; This is a spontaneous report from a non-contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 30Apr2021 at 12:00 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 30Apr2021 at 22:00, the patient experienced muscle and body aches, nausea, decreased appetite, gastrointestinal upset and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events muscle and body aches, nausea, decreased appetite, gastrointestinal upset and fatigue was recovering at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: Muscle and body aches; Nausea; Decreased appetite; Gastrointestinal upset; Fatigue; body aches; This is a spontaneous report from a non-contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 30Apr2021 at 12:00 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 30Apr2021 at 22:00, the patient experienced muscle and body aches, nausea, decreased appetite, gastrointestinal upset and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events muscle and body aches, nausea, decreased appetite, gastrointestinal upset and fatigue was recovering at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Neuralgia
Clinical narrative: Nerve pain in the same leg she had Shingles (fall of 2019).; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9266), via an unspecified route of administration in the left arm on 06Mar2021 at 13:00 (at the age of 45-years-old), as a single dose for COVID-19 immunisation. Medical history included hypothyroid, penicillin allergy and shingles (fall of 2019). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included vilazodone hydrochloride (VIIBRYD), lisdexamfetamine mesilate (VYVANSE), levothyroxine, liothyronine (NP THYROID), lisinopril (LISINOPRIL) and montelukast sodium (SINGULAIR); all from an unknown date for unspecified indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6201) via an unspecified route of administration in the left arm on 13Feb2021 at 13:00 (at the age of 45-years-old), as a single dose for COVID-19 immunisation. On 07Mar2021, the patient experienced nerve pain in the same leg she had shingles (fall of 2019). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event  nerve pain in the same leg she had shingles (fall of 2019) was not resolved at the time of reporting.    No follow-up attempts are possible. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Inflammation
Clinical narrative: Shoulder inflammation; shoulder pain and still persists with a lot pain on sleeping; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER 8729) via an unspecified route on 05Apr2021 at 16:00 in the left arm (at an age of 47-year-old) as single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 17:00, the patient experienced shoulder inflammation and pain where vaccination was administered in the left shoulder which persisted with a lot of pain on sleeping. Therapeutic measures were taken as a result of the events and included treatment with medications (unspecified). The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events of shoulder inflammation and pain where vaccination was administered in the left shoulder which persisted with a lot of pain on sleeping were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Myalgia, Oropharyngeal pain, Pain
Clinical narrative: Fever 101+ degrees; Pain at injection site; Pain at injection site....large lump; Muscle pain; Joint pain; Overall achey; Sore throat; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Apr2021 at 12:00 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included zolpidem (MANUFACTURER UNKNOWN) from an unknown date for unspecified indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 31Mar2021 at 12:00 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. On 23Apr2021 at 03:15, the patient experienced fever 101+ degrees, pain at injection site, large lump, muscle pain, joint pain, overall achey and sore throat; which lasted over three days. Therapeutic measures were not taken as a result of the events. On 23Apr2021 at 03:15, the patient underwent lab test and procedure which included body temperature and result was shown as 101+ degrees. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever 101+ degrees, pain at injection site, large lump, muscle pain, joint pain, overall achey and sore throat were resolved on 25Apr2021.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vaccination site mass, Vaccination site pain
Clinical narrative: Fever 101+ degrees; Pain at injection site; Pain at injection site....large lump; Muscle pain; Joint pain; Overall achey; Sore throat; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Apr2021 at 12:00 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included zolpidem (MANUFACTURER UNKNOWN) from an unknown date for unspecified indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 31Mar2021 at 12:00 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. On 23Apr2021 at 03:15, the patient experienced fever 101+ degrees, pain at injection site, large lump, muscle pain, joint pain, overall achey and sore throat; which lasted over three days. Therapeutic measures were not taken as a result of the events. On 23Apr2021 at 03:15, the patient underwent lab test and procedure which included body temperature and result was shown as 101+ degrees. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever 101+ degrees, pain at injection site, large lump, muscle pain, joint pain, overall achey and sore throat were resolved on 25Apr2021.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Rash erythematous, Rash papular, Rash pruritic
Clinical narrative: rash all over body/random, red raised patches and pop up; random, red raised patches and pop up; random, red raised patches and pop up; itchy rash; This is a spontaneous report from a contactable consumer, the patient. A 19-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8736) via an unspecified route of administration in the right arm on 28Apr2021 at 16:00 (at the age of 19-years-old) as a single dose for COVID-19 immunisation. Medical history included social anxiety, bilateral hip impingement, bilateral labral tears and exercised induced asthma. The patient was allergic to apples, peaches, carrots, red food dye and most plants. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP533) via an unspecified route of administration in the left arm on 07Apr2021 at 16:00 (at the age of 19-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. It was unknown if the patient received any other vaccines within four weeks prior to the vaccination. On 01May2021 at 03:00, the patient had rash all over her body. It was random, red raised patches and pop up and then went away. It was itchy but did not hurt in any way. It was the worst on her chest, torso, hips, and upper thighs. The arm where the patient got the vaccine was mostly fine. The patient had more immediate reaction there. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events rash all over body/random, red raised patches and pop up and itchy rash were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Inappropriate schedule of product administration, Lip discolouration, Pyrexia
Clinical narrative: spiked a 105 fever; chills; uncontrollably shaking; lips turned purple; 01Apr2021 dose 1 Lot number: EW0150 and dose two lot number: Ew0164 administered; This is a spontaneous report from a contactable consumer (patient).   A 43-years-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 via an unspecified route of administration, administered in Arm Left on 01Apr2021 (Batch/Lot Number: Ew0164) as DOSE 2, SINGLE, (at the age of 43 years) dose 1 via an unspecified route of administration, administered in Arm Left on 01Apr2021 13:15 (Batch/Lot Number: EW0150) as DOSE 1, SINGLE  (at the age of 43 years) for covid-19 immunisation.  Medical history included drug hypersensitivity to penicillin and food allergy of banana. Concomitant medication included levothyroxine (LEVOTHYROXINE) taken for an unspecified indication, start and stop date were not reported.  The patient experienced chills on 29Apr2021 15:00 with outcome of recovered, uncontrollably shaking on 29Apr2021 15:00 with outcome of recovered, spiked a 105 fever on 29Apr2021 15:00 with outcome of recovered, lips turned purple on 29Apr2021 15:00 with outcome of recovered and 01Apr2021 dose 1 lot number: EW0150 and dose two given lot number: Ew0164  were administered on 01Apr2021 with outcome of unknown.  The patient underwent lab tests and procedures which included body temperature: 105 on 29Apr2021 "I spiked a 105 fever", sars-cov-2 test: negative on 29Apr2021.  Therapeutic measures were taken as a result of chills, uncontrollably shaking, spiked a 105 fever, lips turned purple.  The husband brought the patient to the emergency room and treatment included IV Benadryl, epinephrine and Tylenol. No other vaccine given within 4 weeks.  The patient did not have COVID prior to vaccine.    No follow up attempts are possible. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, Tremor
Clinical narrative: spiked a 105 fever; chills; uncontrollably shaking; lips turned purple; 01Apr2021 dose 1 Lot number: EW0150 and dose two lot number: Ew0164 administered; This is a spontaneous report from a contactable consumer (patient).   A 43-years-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 via an unspecified route of administration, administered in Arm Left on 01Apr2021 (Batch/Lot Number: Ew0164) as DOSE 2, SINGLE, (at the age of 43 years) dose 1 via an unspecified route of administration, administered in Arm Left on 01Apr2021 13:15 (Batch/Lot Number: EW0150) as DOSE 1, SINGLE  (at the age of 43 years) for covid-19 immunisation.  Medical history included drug hypersensitivity to penicillin and food allergy of banana. Concomitant medication included levothyroxine (LEVOTHYROXINE) taken for an unspecified indication, start and stop date were not reported.  The patient experienced chills on 29Apr2021 15:00 with outcome of recovered, uncontrollably shaking on 29Apr2021 15:00 with outcome of recovered, spiked a 105 fever on 29Apr2021 15:00 with outcome of recovered, lips turned purple on 29Apr2021 15:00 with outcome of recovered and 01Apr2021 dose 1 lot number: EW0150 and dose two given lot number: Ew0164  were administered on 01Apr2021 with outcome of unknown.  The patient underwent lab tests and procedures which included body temperature: 105 on 29Apr2021 "I spiked a 105 fever", sars-cov-2 test: negative on 29Apr2021.  Therapeutic measures were taken as a result of chills, uncontrollably shaking, spiked a 105 fever, lips turned purple.  The husband brought the patient to the emergency room and treatment included IV Benadryl, epinephrine and Tylenol. No other vaccine given within 4 weeks.  The patient did not have COVID prior to vaccine.    No follow up attempts are possible. No further information is expected.